Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy

Leukemia Research

Volumn 35, Issue 8, 2011, Pages 1080-1086

  Amrein, Lilian ^a   Davidson, David ^a   Shawi, May ^a   Petruccelli, Lucas A ^a   Miller, Wilson H ^a   Aloyz, Raquel ^a   Panasci, Lawrence ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

C abl; Chronic lymphocytic leukemia; DNA damage and repair mechanisms; DNA PK; Homologous recombinational repair; Imatinib; Nilotinib; Nonhomologous end joining repair

Indexed keywords

ABELSON KINASE; ABELSON KINASE INHIBITOR; CHLORAMBUCIL; DNA DEPENDENT PROTEIN KINASE; IMATINIB; NILOTINIB; NU 7026; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DNA REPAIR; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME INHIBITION; HOMOLOGOUS RECOMBINATIONAL REPAIR; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LYMPHOCYTE; MONOTHERAPY; NONHOMOLOGOUS END JOINING REPAIR; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, ALKYLATING; B-LYMPHOCYTES; BLOTTING, WESTERN; CHLORAMBUCIL; COMET ASSAY; DNA-ACTIVATED PROTEIN KINASE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; RECOMBINATION, GENETIC; TUMOR CELLS, CULTURED;

EID: 79960273958     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.01.004     Document Type: Article

References (27)

1. Schmid C., Isaacson P.G. Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study. Histopathology 1994, 24:445-451.
2. Messmer B.T., Messmer D., Allen S.L., Kolitz J.E., Kudalkar P., Cesar D., et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005, 115:755-764.
3. Hamblin T.J., Oscier D.G. Chronic lymphocytic leukaemia: the nature of the leukaemic cell. Blood Rev 1997, 11:119-128.
4. Panasci L., Paiement J.P., Christodoulopoulos G., Belenkov A., Malapetsa A., Aloyz R. Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin Cancer Res 2001, 7:454-461.
5. Byrd J.C., Stilgenbauer S., Flinn I.W. Chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2004, 163-183.
6. Eichhorst B.F., Busch R., Stilgenbauer S., Stauch M., Bergmann M.A., Ritgen M., et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009, 114:3382-3391.
7. Riballo E., Kuhne M., Rief N., Doherty A., Smith G.C., Recio M.J., et al. A pathway of double-strand break rejoining dependent upon ATM Artemis, and proteins locating to gamma-H2AX foci. Mol Cell 2004, 16:715-724.
8. Sonoda E., Zhao G.Y., Kohzaki M., Dhar P.K., Kikuchi K., Redon C., et al. Collaborative roles of gammaH2AX and the Rad51 paralog Xrcc3 in homologous recombinational repair. DNA Repair (Amst) 2007, 6:280-292.
9. Christodoulopoulos G., Malapetsa A., Schipper H., Golub E., Radding C., Panasci L.C. Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia. Clin Cancer Res 1999, 5:2178-2184.
10. Bello V.E., Aloyz R.S., Christodoulopoulos G., Panasci L.C. Homologous recombinational repair vis-a-vis chlorambucil resistance in chronic lymphocytic leukemia. Biochem Pharmacol 2002, 63:1585-1588.
11. Muller C., Christodoulopoulos G., Salles B., Panasci L. DNA-Dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards. Blood 1998, 92:2213-2219.
12. Yuan Z.M., Huang Y., Ishiko T., Nakada S., Utsugisawa T., Kharbanda S., et al. Regulation of Rad51 function by c-Abl in response to DNA damage. J Biol Chem 1998, 273:3799-3802.
13. Aloyz R., Grzywacz K., Xu Z.Y., Loignon M., Alaoui-Jamali M.A., Panasci L. Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia 2004, 18:409-414.
14. Daniel R., Wong P.M., Chung S.W. Isoform-specific functions of c-abl: type I is necessary for differentiation, and type IV is inhibitory to apoptosis. Cell Growth Differ 1996, 7:1141-1148.
15. Lin K., Glenn M.A., Harris R.J., Duckworth A.D., Dennett S., Cawley J.C., et al. c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications. Cancer Res 2006, 66:7801-7809.
16. Christodoulopoulos G., Muller C., Salles B., Kazmi R., Panasci L. Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin. Cancer Res 1998, 58:1789-1792.
17. Amrein L., Loignon M., Goulet A.C., Dunn M., Jean-Claude B., Aloyz R., et al. Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase. J Pharmacol Exp Ther 2007, 321:848-855.
18. Willmore E., Elliott S.L., Mainou-Fowler T., Summerfield G.P., Jackson G.H., O'Neill F., et al. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. Clin Cancer Res 2008, 14:3984-3992.
19. O'Hare T., Walters D.K., Stoffregen E.P., Jia T., Manley P.W., Mestan J., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500-4505.
20. Loignon M., Amrein L., Dunn M., Aloyz R. XRCC3 depletion induces spontaneous DNA breaks and p53-dependent cell death. Cell Cycle 2007, 6:606-611.
21. Fabbro D., Manley P.W., Jahnke W., Liebetanz J., Szyttenholm A., Fendrich G., et al. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. Biochim Biophys Acta 2010, 1804:454-462.
22. Deininger M., Buchdunger E., Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105:2640-2653.
23. Kantarjian H.M., Giles F., Gattermann N., Bhalla K., Alimena G., Palandri F., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110:3540-3546.
24. Saglio G., Kim D.W., Issaragrisil S., le Coutre P., Etienne G., Lobo C., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
25. Dorey K., Engen J.R., Kretzschmar J., Wilm M., Neubauer G., Schindler T., et al. Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase. Oncogene 2001, 20:8075-8084.
26. Hebb J.P., Assouline S., Rousseau C., Aloyz R., DesJardins P., Caplan S., et al. A phase I trial of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients. J Clin Oncol (Meet Abstr) 2008, 26:18021.
27. Chow K.U., Nowak D., Hofmann W., Schneider B., Hofmann W.K. Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4. Leukemia 2005, 19:1103-1105. [author reply 5-6; discussion 6-7].